Kite Pharma Inc (KITE) : Simplex Trading added new position in Kite Pharma Inc during the most recent quarter end. The investment management firm now holds 6,394 shares of Kite Pharma Inc which is valued at $356,274 , the company said in a statement filed on Oct 7, 2016 with the SEC.Kite Pharma Inc makes up approximately 0.05% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , First Mercantile Trust Co added KITE to its portfolio by purchasing 1,700 company shares during the most recent quarter which is valued at $94,724. Kite Pharma Inc makes up approx 0.01% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in KITE in the latest quarter, The investment management firm added 1,768 additional shares and now holds a total of 3,301 shares of Kite Pharma Inc which is valued at $186,209.
Kite Pharma Inc opened for trading at $55.58 and hit $57.655 on the upside on Friday, eventually ending the session at $55.72, with a gain of 0.11% or 0.06 points. The heightened volatility saw the trading volume jump to 11,30,601 shares. Company has a market cap of $2,764 M.
On the company’s financial health, Kite Pharma Inc reported $-0.91 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.84. The company had revenue of $4.80 million for the quarter, compared to analysts expectations of $4.78 million. The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Many Wall Street Analysts have commented on Kite Pharma Inc. Shares were Reiterated by Maxim Group on Aug 9, 2016 to “Buy” and Lowered the Price Target to $ 77 from a previous price target of $87 .Company shares were Reiterated by Stifel on Jul 13, 2016 to “Buy”, Firm has raised the Price Target to $ 74 from a previous price target of $63 .
Kite Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT) which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19 is a CAR-based therapy for the treatment of refractory diffuse large B cell lymphoma (DLBCL) primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR KTE-C19CAR and EGFRvlll CAR among others.